TransMedics Group, Inc.
TMDXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, TransMedics Group, Inc. (TMDX) is listed under Medical Devices. With a market capitalization of $3.06B, it sits in mid-cap territory. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Market Cap
$3.06B
Beta
1.88
P/E (TTM)
22.87
P/E (Fwd)
38.29
EPS (TTM)
$3.86
EPS (Fwd)
$2.31
ROE
36.3%
ROA
4.3%
Cash
$472.7M
Total Debt
$867.7M
Free CF
$44.5M
52W Change
-16.5%
Annual Financials
Cash vs Debt
Where TMDX stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, TMDX finished 14.46% below its 150-day moving average ($96.14) and 21.80% below its 200-day moving average ($105.17). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TMDX overbought or oversold?
At the September 2, 2026 close, TMDX's RSI(14) was 41.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
TransMedics Group, Inc. carries $867.7M in total debt against $472.7M in cash reserves — debt is roughly 1.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $44.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 36.3% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $93.5M (2022) to $605.5M (2025), reflecting a 548% increase over the period.
A beta of 1.88 means TMDX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TMDX.